Edwin Ofori Atta: High-Dose Vitamin C and Vascular Function
Edwin Ofori Atta, Head Of Pharmacy at Kumasi Hospital, shared a post on LinkedIn:
“Taking 2 g of vitamin C reduces arterial stiffness by about 9.6 percent within 6 hours and reduces platelet aggregation by about 35%, which may help lower the risk of blood clots.
Specifically high-dose vitamin C reducing arterial stiffness and platelet aggregation within 6 hours, are supported by clinical studies on cardiovascular health.
Vitamin C functions as a powerful antioxidant, scavenging free radicals and improving the bioavailability of nitric oxide.
Increased nitric oxide bioavailability allows blood vessels to relax (vasodilation) and prevents platelets from sticking together.
Double-blind, randomized study found that acute oral administration of high-dose vitamin C significantly increased plasma levels, which reduced the augmentation index (a key measure of arterial stiffness) within 6 hours.
While this study was on healthy individuals, similar studies indicate that vitamin C provides significant cardiovascular benefits by protecting the endothelium (vessel lining) and reducing platelet activation, particularly in individuals with high oxidative stress.”
Stay updated with Hemostasis Today.
-
May 26, 2026, 03:02Spelile Mutupira: Process of Blood Clotting After Injury
-
May 26, 2026, 03:00Clinton Otwori: Which Blood Product Do Healthcare Workers Most Commonly Misunderstand in Practice?
-
May 26, 2026, 02:58Toriqul Islam: EDTA-Induced Pseudothrombocytopenia
-
May 26, 2026, 02:34James O’Donnell Secures 2 Million Euros for a New Programme on The Irish ABO and Coagulation Study – RCSI
-
May 26, 2026, 02:26Joseph R. Shaw: Join The Annual CanVECTOR National Thrombosis Seminar on Precision in DOAC Reversal
-
May 26, 2026, 01:42Mili Doshi: The Role of Oral Health Teams in Supporting Stroke Rehabilitation and Recovery
-
May 26, 2026, 01:25Mohamed Mamdouh: Advancing Stroke Care Access in Cairo Through the Launch of a New Stroke-Ready Center
-
May 26, 2026, 01:15Tom Lazenby: Accelerating Rare Disease Drug Development Through MHRA’s Investigational Marketing Authorisation
-
May 25, 2026, 22:15Cedric Hermans: What Is Still To Be Discovered and To Be Redefined in The Treatment of Haemophilia A?